GlassScriptPhysician profile
Shawn C Koser
NPI 1154025773
$869.26
in general payments reported to CMS, 2019-2025
19 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $204 · 2024: $244 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $147.47 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Ethicon US, LLC | $97.92 | 2023 | Stratafix |
| Astellas Pharma US INC | $90.45 | 2024-2025 | Veozah |
| Novo Nordisk INC | $80.67 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $79.27 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $46.26 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $36.88 | 2025 | |
| Lilly USA, LLC | $35.43 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $32.05 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.94 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $23.22 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.52 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $22.00 | 2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.80 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.08 | 2024 | Xarelto |
| Vivus LLC | $17.71 | 2023 | Qsymia |
| Pfizer INC. | $16.28 | 2024 | |
| Dynavax Technologies Corporation | $8.97 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Koser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.